Lakeshore Biopharma Co, Stock Fundamentals
| LSBCF Stock | 0.84 0.02 2.44% |
Fundamental analysis of LakeShore Biopharma allows traders to better anticipate movements in LakeShore Biopharma's stock price by examining its financial health and performance throughout various phases of its business cycle.
At this time, LakeShore Biopharma's Other Operating Expenses is most likely to increase significantly in the upcoming years. The LakeShore Biopharma's current Research Development is estimated to increase to about 236.2 M, while Selling And Marketing Expenses is projected to decrease to roughly 224.8 M. LakeShore | Select Account or Indicator | Build AI portfolio with LakeShore Stock |
LakeShore Biopharma Co, Company EBITDA Analysis
LakeShore Biopharma's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current LakeShore Biopharma EBITDA | (48.54 M) |
Most of LakeShore Biopharma's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, LakeShore Biopharma Co, is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
LakeShore EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for LakeShore Biopharma is extremely important. It helps to project a fair market value of LakeShore Stock properly, considering its historical fundamentals such as EBITDA. Since LakeShore Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of LakeShore Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of LakeShore Biopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
LakeShore Ebitda
Ebitda |
|
According to the company disclosure, LakeShore Biopharma Co, reported earnings before interest,tax, depreciation and amortization of (48.54 Million). This is 105.53% lower than that of the Healthcare sector and 148.46% lower than that of the Biotechnology industry. The ebitda for all United States stocks is 101.25% higher than that of the company.
LakeShore Biopharma Co, Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining LakeShore Biopharma's current stock value. Our valuation model uses many indicators to compare LakeShore Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across LakeShore Biopharma competition to find correlations between indicators driving LakeShore Biopharma's intrinsic value. More Info.LakeShore Biopharma Co, is considered the number one company in revenue category among its peers. It is rated below average in ebitda category among its peers . At this time, LakeShore Biopharma's Total Revenue is most likely to increase significantly in the upcoming years. Comparative valuation analysis is a catch-all technique that is used if you cannot value LakeShore Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.LakeShore EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses LakeShore Biopharma's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of LakeShore Biopharma could also be used in its relative valuation, which is a method of valuing LakeShore Biopharma by comparing valuation metrics of similar companies.LakeShore Biopharma is currently under evaluation in ebitda category among its peers.
LakeShore Fundamentals
| Revenue | 614.96 M | ||||
| EBITDA | (48.54 M) | ||||
| Net Income | (99.98 M) | ||||
| Total Debt | 414.4 M | ||||
| Cash Flow From Operations | (120.98 M) | ||||
| Number Of Employees | 758 | ||||
| Total Asset | 1.37 B | ||||
| Retained Earnings | (2.41 B) | ||||
| Working Capital | 17.47 M | ||||
| Net Asset | 1.37 B |
About LakeShore Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze LakeShore Biopharma Co,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of LakeShore Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of LakeShore Biopharma Co, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 1.5 M | 1.6 M | |
| Total Revenue | 615 M | 579.8 M | |
| Cost Of Revenue | 107.8 M | 123.2 M | |
| Stock Based Compensation To Revenue | 0.02 | 0.02 | |
| Sales General And Administrative To Revenue | 0.22 | 0.30 | |
| Research And Ddevelopement To Revenue | 0.24 | 0.44 | |
| Capex To Revenue | 0.03 | 0.03 | |
| Revenue Per Share | 5.75 | 10.12 | |
| Ebit Per Revenue | (0.14) | (0.15) |
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Check out LakeShore Biopharma Piotroski F Score and LakeShore Biopharma Altman Z Score analysis. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of LakeShore Biopharma. If investors know LakeShore will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about LakeShore Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of LakeShore Biopharma Co, is measured differently than its book value, which is the value of LakeShore that is recorded on the company's balance sheet. Investors also form their own opinion of LakeShore Biopharma's value that differs from its market value or its book value, called intrinsic value, which is LakeShore Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because LakeShore Biopharma's market value can be influenced by many factors that don't directly affect LakeShore Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between LakeShore Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if LakeShore Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, LakeShore Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.